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Abstract
Background: Lactic acid bacteria (LAB) are beneficial probiotic organisms that contribute to
improved nutrition, microbial balance, and immuno-enhancement of the intestinal tract, as well as
anti-tumor activity. The aim of the present work was to study the growth inhibition of tumor cells
by butanol extract of Bifidobacterium adolescentis isolated from healthy young Koreans.
Methods: The anti-proliferative activity of B. adolescentis isolates was assessed by XTT assays on
three human colon cancer cell lines (Caco-2, HT-29, and SW480). The effects of B. adolescentis
SPM0212 butanol extract on tumor necrosis factor-α (TNF-α) and nitric oxide (NO) production
were tested using the murine macrophage RAW 264.7 cell line.
Results: The butanol extract of B. adolescentis SPM0212 dose-dependently inhibited the growth of
Caco-2, HT-29, and SW480 cells by 70%, 30%, and 40%, respectively, at 200 μg/mL. Additionally,
the butanol extract of B. adolescentis SPM0212 induced macrophage activation and significantly
increased the production of TNF-α and NO, which regulate immune modulation and are cytotoxic
to tumor cells.
Conclusion: The butanol extract of B. adolescentis SPM0212 increased activity of the host immune
system and may improve human health by helping to prevent colon cancer as a biological response
modifier.
Background
Colon cancer is a serious health problem and remains the
leading cause of cancer mortality throughout the world
[1]. Colon cancer incidence has rapidly increased as die-
tary patterns have changed to contain high fat, high pro-
tein, low carbohydrate, and low fiber [2,3]. Colon cancer
is the second most common cancer in Korea [4]. Despite
recent advances in our understanding of the biological
processes resulting in the development of cancer, there
remains a need for new and effective agents to control this
disease.
Microorganisms, such as Mycobacterium bovis, Streptococcus
pyogenes,  Corynebacterium parvum, and cellular compo-
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nents of these bacteria have been used as biological
response modifiers (BRM) and are beneficial adjuvants to
cancer chemotherapy, increasing remission rates and dis-
ease-free intervals. However, the side effect profile in clin-
ical applications for human cancer therapy is important,
as these bacteria are pathogens [5-7].
The health and nutritional benefits of orally administered
probiotic lactic acid bacteria, such as Lactobacillus and Bifi-
dobacteria species, which are a gram-positive and nonpath-
ogenic, has begun to garner an increasing amount of
attention [8,9].
Probiotics, such as lactic acid bacteria (LAB), are living
microorganisms that affect the host in a beneficial manner
by improving nutritional and microbial balance in the
intestinal tract. These probiotic effects increase the
immune response, reduce colon cancer, decrease serum
cholesterol, and produce antimicrobial substances, such
as bacteriocins that inhibit undesirable diarrhea- and dis-
ease-causing pathogens in the human intestine [10-18]. In
addition, the dietary consumption of B. lactis HN019
enhances natural immunity in healthy elderly subjects
[19-21]. Also, viable or heat-killed Lactobacillus and Bifido-
bacterium species, as well as certain of their cell compo-
nents, are capable of stimulating the production of
hydrogen peroxide, nitric oxide (NO), and cytokines, such
as interleukin (IL)-6 and tumor necrosis factor (TNF)-α, in
macrophage cell lines [22-24].
Further, several researchers have studied the anti-tumor
effects exerted by lactic acid bacteria [25-38]. Sekine et al.
detected anti-tumor activity in peptidoglycans isolated
from the B. infantis strain, ATCC 15697, and Oda et al.
reported anti-tumor activity in polysaccharide fractions
originating from Lactobacillus cultures [30,32]. Glycopro-
teins detected in the supernatants of Lactobacillus cultures
also have anti-tumor effects [33]. Many strains, including
L. rhamnosus GG, L. acidophilus, L. casei, B. longum, B. infan-
tis,  B. adolescentis, and B. breve, suppress experimental
colon tumor incidence [27,32-38], but the mechanisms of
this tumor suppression are unclear [18,28,39].
Our goals were to evaluate the effects of Bifidobacterium
adolescentis isolated from fecal samples of healthy young
Koreans on immunostimulation and anti-proliferation of
human colon cancer cell lines in vitro.
Materials and methods
Bacterial Culture
Fecal samples of 20 healthy Koreans (20–30 years old)
were collected by BBL's anaerobic sample collection and
transport system to maintain anaerobic conditions, and
were used within 24 hr. Fecal samples were serially diluted
10-fold from 10-1 to 10-8, and 100 μl was spread onto
selective BL agar containing 5% sheep blood. After 48 hr
of incubation in anaerobic conditions (Bactron Anaerobic
Chamber, Sheldon Manufacturing Inc., USA) at 37°C,
brown or reddish-brown colonies 2–3 mm in diameter
were selected for further identification [40].
A fructose-6-phosphate phosphoketolase (F6PPK) test
was performed [41] to ensure that the colonies selected
were Bifidobacteria, and we analyzed the carbohydrate uti-
lization pattern (Table 1). To identify the isolated Bifido-
bacterium spp. at the species level, 16S rRNA sequencing
was performed by Bioleaders (Daejeon, Korea).
B. adolescentis SPM0212 was cultured at 37°C for 48 hr on
general anaerobic medium (GAM, Nissui Pharm. Co. Ltd.,
Japan) under anaerobic conditions (90% N2, 5% H2, 5%
CO2).
Preparation of B. adolescentis SPM0212 Extract
For the preparation of B. adolescentis SPM0212 butanol
extract, cultures were centrifuged (Vision, USA) at 13,000
rpm for 10 min, then the supernatant was removed and col-
lected bacterial cell pellets were washed with autoclaved
phosphate-buffered saline. These cell pellets were lyophi-
lized, and this powder (0.095 g) was suspended in 50 ml of
distilled water. Then, it was extracted with 50 ml of n-hex-
ane or ethyl acetate or n-butanol. The BuOH fraction was
visibly turbid. The organic solvent of extract was concen-
trated and removed using a rotary vacuum evaporation.
The water, n-hexane, and EtOAc fraction was omitted
because they showed low activity or no suppressive effect
compared with BuOH fraction in the preliminary test.
Table 1: Sugar utilization of Bifidobacterium adolescentis SPM
Sugar Bifidobacterium adolescentis
SPM0212 SPM1005 SPM1601
L-Arabinose - + -
D-Ribose - - -
Xylose + + +
Galactose + + +
Fructose + + +
Mannose - - +
Mannitol - + -
Sorbitol - - -
Salicine - + -
Cellobiose - - +
Maltose + - -
Lactose + + -
Melibiose + + +
Saccharose + + +
Trehalose + + -
Inuline - + -
Melezitose + + -
Raffinose + - +
Starch + + +
Gluconate + - -BMC Cancer 2008, 8:310 http://www.biomedcentral.com/1471-2407/8/310
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Cell Culture
The three human colon cancer cell lines (Table 2) and the
murine macrophage cell line, RAW 264.7, was obtained
from the Korean Cell Line Bank (Seoul, Korea) and the
American Type Culture Collection (ATCC), respectively.
Caco-2, HT-29, and SW480 cells were cultured in Roswell
Park Memorial Institute-1640 (RPMI-1640) medium,
including fetal bovine serum (FBS) and 1% (v/v) penicil-
lin (10,000 U/ml)/streptomycin (10,000 U/ml) (P/S).
RAW 264.7 cells were cultured in Dulbecco's modified
Eagle's medium (DMEM) (with 10% FBS, 1% penicillin/
streptomycin). All cultures were incubated at 37°C in a
humidified atmosphere with 5% CO2. After they were
grown to confluence in 75 cm2  tissue culture flasks
(NunC, Denmark), cells were detached and transferred to
new cell culture dishes in a trypsin-versene mixture (Cam-
brex Bio Science, USA). Cell number and viability were
assessed by the trypan blue dye-exclusion method [42].
Tumor Cell Proliferation by XTT Assay
Cell proliferation was quantified via an XTT assay
(sodium 3-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-
bis(4-methoxy-6-nitro)benzene sulfonic acid hydrate).
Cells were seeded on 96-well microplates (NunC, Den-
mark) at 3 × 103 cells/well and incubated for 72 hr with
the test compounds. Control was only cells (no treated).
The butanol extract (no cells) was not tested. The samples
were then incubated with 50 μl of XTT solution (1 mg/ml)
for 6 hrs and measured with an ELISA reader (Molecular
Devices, USA) at 490 nm.
Tumor Necrosis Factor-α (TNF-α) Quantification
RAW 264.7 (1 × 105  cells/ml), LPS (Escherichia coli
O127:B8 Westphal type, 100 ng/mL), and test samples
(12.5, 25, 50, 100, 200 μg/ml) were prepared as treated
groups and incubated for 48 hr. Following incubation,
TNF-α secretion was assessed with an OPTEIA™ Mouse
TNF-α kit (Pharmingen, San Diego, CA, USA) in accord-
ance with manufacturer's protocol. Briefly, the sample
and recombinant standards were added to antibody-
coated plates and incubated for 2 hr. TNF-α was detected
via the addition of horseradish peroxidase-conjugated,
streptavidin-labeled antibodies. Color was developed
using tetramethylbenzidine (TMB) (BD Biosciences,
Pharmingen, USA) for 30 min and the absorbance was
recorded at 450 nm.
Nitric Oxide Assay
RAW 264.7 cells (1 × 106 cells/ml), LPS (50 ng/ml), and
test samples (12.5, 25, 50, 100, 200 μg/ml) were prepared
and incubated overnight. One hundred microliters from
the surface of cultures was transferred into a new plate and
the equivalent amount of Griess reagent was added
(Stock-1: 0.2% naphylendia HCl, Stock-2: 2% sulfanila-
mide in 5% H3PO4). This plate was then incubated for 10
min at RT and measured by an ELISA reader at 540 nm.
Standard calibration curves were prepared using sodium
nitrite as a standard.
Effect of B. adolescentis SPM0212 on Macrophage 
Morphology
RAW 264.7 cells (1 × 103 cells/well) were cultured in ster-
ile glass-slide chambers for 48 hr. The culture medium
was removed, and the cells were treated with either LPS
(100 ng/ml) or samples of B. adolescentis SPM0212 (12.5,
25, 50, 100, 200 μg/ml) for 48 hr. Following treatment,
the culture supernatant was removed, and the cells were
fixed and stained in Diff Quick Solution (Baxter, Hou-
ston, TX). Macrophage morphology was observed using a
light microscope (BX41, Olympus, Japan) at 400× magni-
fication.
Statistical Analysis
All data were expressed as the mean ± standard deviation
(SD). For statistical evaluation of data, one-way ANOVA
was applied using the program SPSS 13.0 for Windows.
This was followed by post hoc comparisons using the
Tukey's test. Significant differences were considered signif-
icant at P < 0.05.
Results
B. adolescentis Strains Inhibit the Growth of Colon 
Cancer Cell Lines
To determine whether B. adolescentis strains inhibit the
growth of the colon cancer cell lines, Caco-2, HT-29, and
SW 480, cells were treated with 3 different B. adolescentis
isolates, and XTT assays were performed. B. adolescentis
SPM0212 exhibited the highest efficacy (data not shown).
To further characterize the functional substances of B. ado-
lescentis  SPM0212, the cell lines were treated with the
butanol extract of this strain. The butanol extract signifi-
cantly inhibited proliferation of both Caco-2 and SW480
cell lines, with inhibition of Caco-2 and SW480 growth by
70% and 40%, respectively, at 200 μg/ml (Figure 1). Treat-
Table 2: Characteristics of cell lines used in this study (KCLB, Korean Cell Line Bank)
Cell line Cell type Origin Growth property KCLB (ATCC) No.
Caco-2 Epithelioid Colonic adenocarcinoma Adherent KCLB 30037
HT-29 Epithelioid Colonic adenocarcinoma Adherent KCLB 3003
SW480 Epithelioid Colonic adenocarcinoma Adherent KCLB 10228BMC Cancer 2008, 8:310 http://www.biomedcentral.com/1471-2407/8/310
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ment with the same concentration of butanol extract also
decreased proliferation of HT-29, but there was no signif-
icant difference.
Effect of B. adolescentis SPM0212 on TNF-α and NO 
Production
Next, we examined the effects of B. adolescentis SPM0212
butanol extract on TNF-α and NO production by the mac-
rophage RAW 264.7 cell line (Figure 2 and 3, respec-
tively).  B. adolescentis SPM0212 butanol extract
significantly increased TNF-α production in a dose-
dependent manner from 25 μg/ml to 200 μg/ml (Figure
2). Treatment with 200 μg/ml of butanol extract produced
more TNF-α than LPS treatment, which was used as a pos-
itive control for macrophage activation. Treatment of
RAW 264.7 cells with B. adolescentis SPM0212 butanol
extract also increased production of NO (Figure 3). How-
ever, increases in TNF-α and NO production by B. adoles-
centis  SPM0212 culture supernatant were not observed
(data not shown).
Morphology of RAW 264.7 cells treated with B. 
adolescentis SPM0212
Normal RAW 264.7 cells, when cultured in medium
alone, look refractile and rounded morphology and do
Effects of growth inhibition by B. adolescentis SPM0212 on  colon cancer cell lines (Caco-2, HT-29 and SW480) Figure 1
Effects of growth inhibition by B. adolescentis 
SPM0212 on colon cancer cell lines (Caco-2, HT-29 
and SW480). The cells (1 × 103 cells/well) were treated 
with B. adolescentis SPM0212 butanol extract (25, 50, 100, 
200 μg/ml), and incubated for 72 hr at 37°C and 5.5% CO2. 
After adding 50 μl of the XTT labeling mixture, they were 
incubated for 6 hr at 37°C in 5.5% CO2. The absorbance was 
measured using an ELISA reader at 490 nm. The quantitative 
data were presented as means ± SD of three independent 
experiments. Control versus treatment groups, *p < 0.05; 
**p < 0.01.
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Effects of B. adolescentis SPM0212 on TNF-α production from  RAW 264.7 cells Figure 2
Effects of B. adolescentis SPM0212 on TNF-α produc-
tion from RAW 264.7 cells. The cells (1 × 103 cells/well) 
were treated with LPS (100 ng/ml) or butanol extract of B. 
adolescentis SPM0212 (25, 50, 100, 200 μg/ml), and incubated 
for 48 hr at 37°C and 5.5% CO2. The extracellular levels of 
TNF-α in the culture media were determined by an ELISA 
reader at 450 nm. The quantitative data were presented as 
means ± SD of three independent experiments. Control ver-
sus B. adolescentis SPM0212 butanol extract, *p < 0.05; **p < 
0.01.
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Effects of B. adolescentis SPM0212 on NO production from  RAW 264.7 cells Figure 3
Effects of B. adolescentis SPM0212 on NO production 
from RAW 264.7 cells. The cells (1 × 103 cells/well) were 
treated with LPS (50 ng/ml) or butanol extract of B. adoles-
centis SPM0212 (25, 50, 100, 200 μg/ml), and incubated for 22 
hr at 37°C and 5.5% CO2. Nitrite concentrations in the cul-
ture media were determined using Griess reagent assay and 
measured by ELISA reader at 540 nm. The quantitative data 
were presented as means ± SD of three independent experi-
ments. Control versus B. adolescentis SPM0212 butanol 
extract, *p < 0.05; **p < 0.01.
** **
**
**
0
2
4
6
8
10
12
14
16
18
20
Cell LPS 25 50 100 200
N
i
t
r
i
t
e
 
(
μ
M
)
(50 ng/ml)                                  Concentration (μl/ml)
of extract of B. adolescentisBMC Cancer 2008, 8:310 http://www.biomedcentral.com/1471-2407/8/310
Page 5 of 8
(page number not for citation purposes)
Characterization of RAW 264.7 cells in response to butanol extract of B. adolescentis SPM0212 Figure 4
Characterization of RAW 264.7 cells in response to butanol extract of B. adolescentis SPM0212. RAW 264.7 cells 
(1 × 104 cells/well) were cultured on cover slips in the presence of different concentrations of butanol extract of B. adolescentis 
SPM0212 for 48 hr. The cells were fixed and stained in Diff-quick and observed under a light microscope at 400×. (A) Murine 
macrophage cells. (B) LPS (50 ng/ml). (C) Butanol extract of B. adolescentis SPM0212 (25 μg/ml). (D) Butanol extract of B. ado-
lescentis SPM0212 (50 μg/ml). (E) Butanol extract of B. adolescentis SPM0212 (100 μg/ml). (F) Butanol extract of B. adolescentis 
SPM0212 (200 μg/ml).
BMC Cancer 2008, 8:310 http://www.biomedcentral.com/1471-2407/8/310
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not spread over the surface (Figure 4A). Activated macro-
phages usually display a distinct morphology, which is
similar to the dendritic cell. Exposure to LPS (50 ng/ml;
the positive control) induced morphological alteration of
the RAW 264.7 cells (Figure 4B). Treatment with B. adoles-
centis SPM0212 butanol extract caused RAW 264.7 cells to
become larger and rougher in a dose-dependent manner,
suggesting activation (Figure 4C–F).
Discussion
Bifidobacterium spp., and LAB, are probiotic organisms in
humans and stimulate immune function and anti-tumor
effects [19-45]. Although the precise mechanisms by
which LAB inhibit colon cancer are not known, several
have been proposed: (a) enhancing the host immune
response, (b) binding and degrading potential carcino-
gens, (c) alterations in the intestinal microflora that pro-
duce putative carcinogens, (d) production of anti-
tumorigenic or anti-mutagenic compounds in the colon,
and (e) alteration of metabolic activities of intestinal
microflora [18,46-49].
LAB play an important role in the host immune system to
produce anti-tumor effects [50-52]. Macrophages play a
major role in the host defense against infection and tumor
formation [53], and their function can be altered by a vari-
ety of stimulatory and suppressive signals and environ-
mental factors. [54,55]. The production of nitric oxide
(NO) and tumor necrosis factors (TNF-α) by macro-
phages mediate killing and growth inhibition of tumor
cells, bacteria, fungi, and parasites [56]. TNF-α is a non-
glycosylated 17 kDa protein that exists as a trimer in solu-
tion, has receptors on almost all somatic cells, regulates
immune modulation, and is cytotoxic to tumor cells
[57,58]. Also, TNF-α and reactive nitrogen intermediates
play major roles in the in vitro anti-tumor activity of
mouse peritoneal exudates from mice stimulated with
wall peptidoglycan from B. infantis [32]. Therefore,
cytokine production is a good measure of macrophage
activation and further understanding of how Bifidobacte-
rium affects the production of macrophage mediators may
clarify how this strain affects immune function and tumor
cells at the cellular level [22].
This study showed that the butanol extract of B. adolescen-
tis SPM0212 increased secretion of TNF-α and NO from
the macrophage RAW 264.7 cell line, as well as changed
cell morphology. The butanol extract may contain key fac-
tors for increased macrophage activation and inhibition
of tumor cell proliferation. Moreover, the butanol extract
of B. adolescentis SPM0212 exerted direct anti-proliferative
activity against three human colon cancer cell lines. We
also observed that butanol extract of B. adolescentis
SPM0212 – caused death of Caco-2, HT-29 and SW480
cells without any cytotoxicity to nonneoplastic epithelial
cell (data not shown). Here, B. adolescentis SPM0212
potentiated TNF-production and may be beneficial in
human intestinal tracts for immune reinforcement [59].
In contrast, most previously reported polysaccharides that
exhibit anti-tumor activities did not directly inhibit the
growth of tumor cells in vitro, but instead exerted anti-
tumor activity by stimulating macrophages and immune
responses. Therefore, the direct inhibitory effect by the
butanol extract on tumor cell growth observed in this
study is exceptional for polysaccharide biomaterials, but
the active components remain to be elucidated. Further
studies are needed to identify the effective components in
the B. adolescentis SPM0212 butanol extract and will be
required to clarify the precise mechanisms of this inhibi-
tion.
Conclusion
Bifidobacteria strains have health-promoting effects. Our
results showed that the butanol extract of B. adolescentis
SPM0212, isolated from fecal samples of healthy young
Koreans, markedly and dose-dependently decreased the
proliferation of three human colon cancer cell lines, Caco-
2, HT-29, and SW480. In addition, the butanol extract
increased the production of the macrophage mediators,
TNF-α and NO, and changed macrophage RAW 264.7 cell
morphology. Therefore, this extract could potentially help
to enhance the host immune system and improve human
health by helping to prevent colon cancer as a biological
response modifier (BRM).
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